Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Douglas A MataJessica K LeeVignesh ShanmugamChelsea B MarcusAlexa B SchrockErik A WilliamsLauren L RitterhouseRichard A HickmanTyler JanovitzNimesh R PatelBenjamin R KrogerJeffrey S RossKamran M MirzaGeoffrey R OxnardJo-Anne VergilioJulia A ElvinJamal K BenhamidaBrennan DeckerMina L XuPublished in: Histopathology (2024)
These data demonstrate that LBx can detect relevant genomic alterations across HNs, including at low clonal fractions, suggesting a potential clinical utility for identifying residual or emerging therapy-resistant clones that may be undetectable in site-specific tissue biopsies.
Keyphrases
- ultrasound guided
- computed tomography
- circulating tumor
- electronic health record
- image quality
- bone marrow
- dendritic cells
- cell free
- dual energy
- contrast enhanced
- acute myeloid leukemia
- single molecule
- fine needle aspiration
- big data
- copy number
- ionic liquid
- positron emission tomography
- gene expression
- nucleic acid
- immune response
- dna methylation
- artificial intelligence
- cell therapy
- data analysis
- replacement therapy